【SynerG】The company's outstanding balance of capital loans has reached the announcement standard of Article 22, Paragraph 1, Subparagraph 3 of the 'Regulations Governing Loaning of Funds and Endorsements/Guarantees by Public Companies'

1. Date of occurrence of the event: 2026/05/06
2. Recipient of capital loans:
(1) Company name: Jih Ho Medical Instruments Co., Ltd.
(2) Relationship with the company providing capital loans: 100% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 200,000
(5) Amount of new capital loan (NT$ thousand): 100,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 300,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Duo Mo Shi Co., Ltd.
(2) Relationship with the company providing capital loans: 100% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 450,000
(5) Amount of new capital loan (NT$ thousand): 50,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 500,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Shin Hwa Bio-Tech Co., Ltd.
(2) Relationship with the company providing capital loans: 100% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 600,000
(5) Amount of new capital loan (NT$ thousand): 100,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 700,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Jiu He Bio-Tech Co., Ltd.
(2) Relationship with the company providing capital loans: 100% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 60,000
(5) Amount of new capital loan (NT$ thousand): 30,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 90,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Dong Lin Instruments Co., Ltd.
(2) Relationship with the company providing capital loans: 100% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 60,000
(5) Amount of new capital loan (NT$ thousand): 30,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 90,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Hualin Co., Ltd.
(2) Relationship with the company providing capital loans: 100% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 0
(5) Amount of new capital loan (NT$ thousand): 30,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 30,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Fuh Kang Vitality Pharmaceutical Co., Ltd.
(2) Relationship with the company providing capital loans: 50% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 200,000
(5) Amount of new capital loan (NT$ thousand): 50,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 250,000
(8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: SynerG Bio-Medical Long-Term Care Social Welfare Corporation
(2) Relationship with the company providing capital loans: Over 50% owned subsidiary
(3) Limit on capital loans (NT$ thousand): 762,952
(4) Original outstanding loan balance (NT$ thousand): 0
(5) Amount of new capital loan (NT$ thousand): 20,000
(6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes
(7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 20,000
(8) Reason for new capital loan: Operating funds required by the subsidiary
3. Collateral provided by the recipient of capital loans:
(1) Content: None
(2) Value (NT$ thousand): 0
4. Latest financial report of the recipient of capital loans:
(1) Capital (NT$ thousand): 6,686,065
(2) Accumulated profit/loss (NT$ thousand): 113,103
5. Interest calculation method:
Calculated from the borrowing date, interest rate 2%~3.5%.
6. Repayment:
(1) Terms: Repaid within one year from the borrowing date, depending on financial situation.
(2) Date: Repaid within one year from the borrowing date.
7. Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 2,905,000
8. Ratio of outstanding capital loan balance to the net worth of the public company's latest financial report as of the date of occurrence: 38.00%
9. Source of company's funds lent to others: Parent company
10. Other matters that should be specified: None